Compare prices and buy KPV from 41 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic tripeptide (Lys-Pro-Val, CAS 67727-97-3) corresponding to the three C-terminal amino acids (residues 11-13) of alpha-melanocyte-stimulating hormone. Despite its alpha-MSH origin, KPV's anti-inflammatory activity appears not to be mediated by melanocortin receptors. In cell studies it enters intestinal epithelial and immune cells through the PepT1 oligopeptide transporter and suppresses NF-kB signaling, reducing pro-inflammatory cytokine release. The evidence for it is preclinical, chiefly rodent colitis models, and it is not FDA-approved.
For research purposes only. Not medical advice.
KPV is a synthetic tripeptide (Lys-Pro-Val) corresponding to residues 11-13 of alpha-melanocyte-stimulating hormone (alpha-MSH), the last three amino acids of that 13-residue hormone.
Despite the alpha-MSH origin, KPV's reported anti-inflammatory activity does not appear to be melanocortin-receptor mediated. Binding at the melanocortin receptors MC1R through MC5R depends on the core "message" sequence His-Phe-Arg-Trp at residues 6-9, which the tripeptide does not contain. Instead, cell and rodent work describes KPV entering intestinal epithelial and immune cells through PepT1 (SLC15A1), the proton-coupled oligopeptide transporter that normally absorbs di- and tripeptides from digested protein, and then suppressing activation of NF-kB and MAP kinase signaling, which lowers downstream synthesis of pro-inflammatory cytokines including IL-6, IL-8 and TNF-alpha.
PepT1 is expressed at low levels in healthy colon and is upregulated in inflamed intestinal tissue, so the proposed uptake would concentrate where inflammation already is. The non-melanocortin mechanism also separates KPV cleanly from Melanotan II, the cyclic alpha-MSH analog sold precisely for its melanocortin activity: the two share a parent hormone and essentially nothing else.
The KPV literature is small, preclinical, and concentrated in a handful of laboratories. The most cited work comes from Didier Merlin's group, then at Emory University, which reported in Gastroenterology in 2008 that PepT1-mediated uptake of KPV reduced inflammation in two mouse models of colitis. Follow-up work from the same group and its collaborators tested nanoparticle and hydrogel delivery systems intended to release the tripeptide in the colon rather than the upper gut.
No controlled human trial of KPV has been completed or published for any indication. FDA's briefing document for the July 2026 advisory meeting says its search identified no clinical studies of KPV in humans and that the nominator provided no clinical evidence for wound healing or inflammatory conditions.
KPV is not approved by the FDA for any indication. Its status inside the US compounding system has moved twice in three years:
The recommendation is non-binding: the 503A list changes only through notice-and-comment rulemaking, and as of October 2026 the Federal Register carries no proposed rule naming KPV. A fuller account is in our writeup of the July 2026 PCAC vote, which covers the other six substances heard the same week, among them BPC-157 and TB-500. Even a favorable rule would only let 503A pharmacies compound KPV for individual prescriptions, which does not make it an approved drug, and it would not change the status of research-grade KPV sold by peptide vendors, which is offered for laboratory use only and not for human consumption.
KPV is usually sold under its own initials, sometimes with its sequence attached, as in "KPV (Lys-Pro-Val)." Some vendors list it as "alpha-MSH (11-13)," which is the same compound described by its position in the parent hormone.
PeptideScouter indexes KPV per milligram and verifies identity against its molecular formula (C16H30N4O4, CAS 67727-97-3).
No. KPV is not approved by the FDA for any indication and has no completed controlled human trials. Its compounding status has moved twice: the FDA placed it in Category 2 of the interim 503A bulk drug substances list in September 2023, removed it from Category 2 in April 2026, and on July 23, 2026 the Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend adding it to the 503A list. That vote is a non-binding recommendation, not an approval, and adding it to the list still requires notice-and-comment rulemaking. In October 2026 HHS said it does not intend to take enforcement action against pharmacies and physicians compounding KPV acetate under set conditions until a final rule decides the listing. Material sold by research vendors is for laboratory use only and not for human consumption.
No. KPV is the last three amino acids of alpha-melanocyte-stimulating hormone, residues 11-13 of a 13-residue hormone. It lacks the His-Phe-Arg-Trp core sequence that alpha-MSH uses to bind the melanocortin receptors, so it is not expected to carry the pigmentation or appetite activity associated with the full hormone or with analogs such as Melanotan II. There is also a chemical difference most product pages skip: the C-terminal valine is amidated in alpha-MSH itself, while the tripeptide sold under CAS 67727-97-3 is the free acid.
In preclinical research, KPV has been studied as an anti-inflammatory tripeptide. The mechanism most often described is uptake into intestinal epithelial and immune cells through the PepT1 oligopeptide transporter, followed by suppression of NF-kB and MAP kinase signaling and reduced production of pro-inflammatory cytokines such as IL-6, IL-8 and TNF-alpha. Most of the published work is in rodent models of colitis and in cell culture. No controlled human trial has been completed, so KPV's effects in people are not established.
KLOW is a four-peptide product combining GHK-Cu, TB-500, BPC-157 and KPV, marketed as adding anti-inflammatory coverage on top of the three-peptide GLOW combination. PeptideScouter catalogues blends as their own rows rather than folding them into the single-compound listings, because a per-milligram price averaged across four different peptides at different ratios cannot be compared to the per-milligram price of KPV on its own.
KPV is sold by 41 research peptide vendors indexed on PeptideScouter, with 70 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
39 of the 41 indexed vendors currently have KPV in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Helixion Labs currently lists KPV at $1.45/mg, the lowest listed price across 41 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.30/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 41 vendors listing KPV publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $1.45/mg listed to $1.30/mg at Helixion Labs. Each vendor's code is shown beside its price in the table above.
KPV ranges from $1.45/mg to $8.00/mg across 70 listings from 41 research peptide vendors, normalized to USD per milligram and refreshed daily.
41 research peptide vendors currently list KPV on PeptideScouter, with 39 in stock right now. We track 70 listings across size and kit variants.
KPV's CAS Registry Number is 67727-97-3. It is also sold as KPV (Lysine-Proline-Valine).
